Table 2. Five-year survival probabilities±s.e. in percentages for recurrence-free survival (RFS), and overall survival (OS).
| RFS | OS | ||
|---|---|---|---|
| Variables | N | % (±s.e.) | % (±s.e.) |
| All | 228 | 68 (3) | 67 (3) |
| Menopausal status | |||
| Pre | 68 | 67 (6) | 74 (5) |
| Post | 160 | 68 (4) | 64 (4) |
| P=0.926 | P=0.011 | ||
| Tumour size (mm) | |||
| ⩽20 | 86 | 83 (4) | 81 (4) |
| 21–50 | 132 | 59 (4) | 59 (4) |
| >50 | 10 | 40 (15) | 40 (15) |
| P=0.0004 | P=0.0002 | ||
| Histological malignancy grade | |||
| I (ductal) | 36 | 88 (5) | 92 (5) |
| II (ductal) | 87 | 66 (5) | 69 (5) |
| III (ductal) | 74 | 55 (6) | 49 (6) |
| Other (nonductal) | 31 | 76 (8) | 74 (8) |
| P=0.0061 | P=0.0007 | ||
| Receptor status | |||
| Positive | 174 | 69 (4) | 68 (4) |
| Negative | 54 | 64 (7) | 63 (7) |
| P=0.881 | P=0.857 | ||
| Lymph node metastasis | |||
| None | 101 | 75 (4) | 77 (4) |
| 1–3 | 78 | 78 (5) | 72 (5) |
| ⩾4 | 49 | 37 (7) | 37 (7) |
| P<0.0001 | P<0.0001 | ||
| Chalkley count (points) | |||
| ⩽5 | 75 | 84 (4) | 84 (4) |
| 5–7 | 72 | 61 (6) | 68 (5) |
| ⩾7 | 81 | 58 (6) | 49 (6) |
| P=0.0029 | P<0.0001 | ||
| PAI-1 (ngmg−1 total protein) | |||
| ⩽11.1 | 117 | 79 (4) | 74 (4) |
| >11.1 | 111 | 56 (5) | 59 (5) |
| P=0.0001 | P=0.0004 | ||
| uPA (ngmg−1 total protein) | |||
| ⩽4.5 | 113 | 75 (4) | 73 (4) |
| 4.5 | 115 | 60 (5) | 60 (5) |
| P=0.0328 | P=0.0354 | ||
Significant differences in survival probabilities between the groups are given in bold.